19 results about "Arg-Gly-Ser" patented technology

The invention discloses a cyclic nonapeptide with repairing and anti-oxidation effects and application of the cyclic nonapeptide, the amino acid sequence of the cyclic nonapeptide is cyclic (arginine-glycine-aspartic acid-serine-arginine-lysine-valine-lysine-serine), the prepared cyclic nonapeptide has the repairing and anti-oxidation effects, and the cyclic nonapeptide has the repairing and anti-oxidation effects. The composition can be applied to preparation of cosmetics with repairing and / or anti-oxidation effects.

The invention discloses efficient synthesis of guanidinoacetic acid by a carbamyl phosphoric acid synthesis-enhanced multi-enzyme cascade system, and belongs to the field of biological catalysis engineering. The invention provides a dominant mutant E31K / G351N of L-arginine: glycine amidino transferase, the catalytic efficiency of guanidinoacetic acid is improved by 34.6% compared with that of wild type, an eight-enzyme synergistic arginine circulation system is subsequently constructed based on a mutant strain, 18.35 g / L GAA (56.75 mM) is realized by a 5L fermentation tank, the arginine conversion rate reaches 261.12%, and the yield of the glycine amidino transferase is greatly improved. The highest level of catalytic synthesis of guanidinoacetic acid by escherichia coli is publically reported at home and abroad at present. According to the research, an efficient technical route is provided for GAA industrial production, and a universal strategy framework is established for rational design of a multi-enzyme system and multi-gene co-expression optimization.

The present invention discloses an L-arginine-glycine amidinotransferase and use thereof in the production of guanidinoacetic acid. In the present invention, through combined multi-site amino acid mutation, a technical effect of significantly improved enzyme activity of the mutant AkAGATT225Q / A258P / L278K than that of the wild-type strain is achieved, providing an application value for large-scale production of guanidinoacetic acid in industry. When the L-arginine-glycine amidinotransferase mutant constructed in the present invention is used in the production of guanidinoacetic acid, by optimizing the conversion conditions, the yield of guanidinoacetic acid is up to 21.4 g / L and the conversion rate is 90.4%, after 24 hrs of reaction in a 1 L reaction system. Compared with the production of guanidinoacetic acid with the raw enzyme, the yield is increased by 49.6%.

The invention discloses a modified silk fibroin artificial blood vessel and a preparation method and application thereof.The modified silk fibroin artificial blood vessel comprises a modified silk fibroin composite scaffold and a polyurethane layer, the polyurethane layer is arranged on the modified silk fibroin composite scaffold through electrostatic spinning, and the polyurethane layer is prepared from polyurethane, the modified silk fibroin composite scaffold is prepared from the following raw materials: modified silk fibroin, arginine-glycine-aspartic acid polypeptide modified polycaprolactone, bacterial cellulose, a growth factor and glutaraldehyde. The modified silk fibroin is in bridge connection with the arginine-glycine-aspartic acid polypeptide modified polycaprolactone and is loaded with the growth factor. The comprehensive biocompatibility of the artificial blood vessel can be improved, thrombosis and intimal hyperplasia are effectively inhibited, and therefore the long-term patency rate of the small-caliber artificial blood vessel is greatly increased.

The application discloses a cyclic nonapeptide with a skin barrier repair effect and application thereof, and the amino acid sequence of the cyclic nonapeptide is: cyclic (arginine-glycine-aspartic acid-serine-phenylalanine-lysine-valine-lysine-lysine). The cyclic nonapeptide can obviously improve the gene expression of FLG and AQP3, and reduce the gene expression of TNF-alpha and NF-kappa B, thereby having the skin barrier repair effect, and can be applied to skin barrier repair cosmetics, drugs or health foods as an effective component.

The invention relates to the field of dermatology and cosmetology and can be used for regenerating wounds and preventing and correcting age-related skin changes, as well as for stimulating hair growth. The proposed composition contains as active ingredient the secretome of mesenchymal stromal cells (MSCs) derived from mammalian adipose tissue, the secretome being provided in an amount of 50-70 ‎μg / ml and being characterized by the presence of the following secretion products: FGF-2, KGF, TGF-β, PDGF, TGF-α, IGF-1, EGF, HGF, VEGF, G-CSF, GM-CSF, PGE2, ANG-1, ANG-2, MCP-1, MMPs, cysteine, tyrosine, arginine, glycine, histidine, isoleucine, lysine hydrochloride, methionine, phenylalanine, serine, threonine, tryptophan and valine. Also proposed is a method for producing the claimed composition, which includes techniques and conditions for harvesting and cultivating MSCs, making it possible to obtain a secretome having constituents effective for the treatment and regeneration of skin and hair.

This invention discloses a cyclic nonapeptide with both anti-photoaging and antioxidant effects. The amino acid sequence of the cyclic nonapeptide is: cyclic (arginine-glycine-aspartic acid-serine-asparagine-lysine-valine-lysine-phenylalanine). The cyclic nonapeptide of this invention can effectively reduce deep photoaging caused by UVA and surface oxidative damage induced by UVB, thereby achieving comprehensive skin protection.

The present invention relates to a microorganism containing at least one heterologous gene encoding L-arginine:glycine amidinotransferase (AGAT), at least one heterologous L-threonine 3-dehydrogenase gene (tdh), and at least one heterologous glycine C-acetyltransferase (2-amino-3-oxobutanoate coenzyme A ligase) gene (kbl), as well as a method for the fermentative production of guanidinoacetic acid (GAA) using such a microorganism. The present invention also relates to a method for the fermentative production of creatine.

The invention discloses a cyclic nonapeptide with anti-oxidation, soothing and anti-inflammatory effects. The amino acid sequence of the cyclic nonapeptide is as follows: cyclic (arginine-glycine-aspartic acid-serine-glutamine-lysine-valine-lysine-arginine). The invention discloses a novel cyclic nonapeptide which is capable of effectively eliminating ROS (reactive oxygen species) and inhibiting secretion of inflammatory factors, and has an antioxidant effect and an anti-inflammatory relieving capability.

The invention relates to the technical field of biomedical engineering, and discloses a diabetes wound repair stent with a bionic vascular network structure, comprising: a stent main body which is made of a biocompatible high polymer material and has a three-dimensional bionic vascular network structure built by a 3D printing technology inside, and the structure simulates hierarchical branching and connectivity of natural blood vessels; the bioactive factor loading unit comprises a vascular endothelial growth factor and mesenchymal stem cells, and the vascular endothelial growth factor is loaded in the stent through a microsphere encapsulation technology to form a space-time controllable release system; the surface functional modification layer is used for fixing vascularization promoting polypeptide on the surface of the stent main body through chemical grafting, and the polypeptide sequence comprises an arginine-glycine-aspartic acid structural domain. By means of the precisely-designed 3D printing bionic blood vessel network structure, grading branching and connectivity of natural blood vessels are effectively simulated, the blood vessel guiding efficiency is improved, and the blood vessel ingrowth speed is increased by two times or above.

This invention discloses a cyclic nonapeptide with skin barrier repair and anti-inflammatory effects. The amino acid sequence of the cyclic nonapeptide is: cyclic (arginine-glycine-aspartic acid-serine-arginine-lysine-valine-lysine-tryptophan). The cyclic nonapeptide of this invention can increase the relative expression levels of lobe rhabdominis (LOR), filaggrin (FLG), and aquaporin 3 (AQP3) genes, and reduce the secretion of inflammatory factors IL-6 and IL-8, thereby exhibiting skin barrier repair and anti-inflammatory effects.

The invention discloses a scalp care composition containing a kangaroo claw extract. The scalp care composition is prepared from the following components: the kangaroo claw extract, arginine, glycine and soluble 17-type collagen. The invention further discloses a preparation method and application of the scalp care composition. According to the composition disclosed by the invention, the kangaroo claw extract-arginine-glycin-17 type collagen is compounded and combined, so that the activity of MMP-12 is inhibited, and the generation of elastin fragments is reduced; the expression of CyclinD1 is up-regulated, and the cell cycle of the hair papilla is activated; the inflammatory factor level is reduced, the scalp steady state is recovered, and the health state of the scalp microenvironment can be comprehensively and effectively maintained.

The present application relates to a kind of polypeptides, and specifically relates to a kind of tumor targeting peptide and its application;Tumor targeting peptide p46-2 is the carboxyl end of the 361-382 fragment of human cell tumor antigen p53 by connecting peptide and tumor targeting fragment arginine-glycine-aspartic acid-arginine connection;Chemotherapy drugs include paclitaxel, epirubicin, 5 fluorouracil;Selected tumor types include breast cancer, colorectal cancer.Tumor targeting polypeptide and classic chemotherapy drug combination therapy tumor, can obviously achieve the effect of drug synergism.

This peptide, or a pharmaceutically acceptable salt thereof, contains a substructure having an amino acid sequence selected from the group consisting of (1) and (2). (1) Amino acid sequence represented by formula (I): RYRYYGHNLIAYGFY (SEQ ID NO: 1); (2) Amino acid sequence represented by formula (I) with 1 to 6 amino acids substituted, where, when the arginine at the N terminus is defined as the first amino acid residue, the first amino acid residue is optionally substituted with a basic amino acid other than arginine and histidine; the second amino acid residue is optionally substituted with an aromatic amino acid other than tyrosine and histidine; the third amino acid residue is optionally substituted with a basic amino acid other than arginine and histidine; the fourth amino acid residue is optionally substituted with an aromatic amino acid other than tyrosine and histidine; the fifth amino acid residue is optionally substituted with an aromatic amino acid other than tyrosine and histidine or an amino acid containing a hydroxy group; the sixth amino acid residue is optionally substituted with alanine or an analog thereof, or a glycine analog; the seventh amino acid residue is optionally substituted with an amino acid other than cysteine, lysine, proline, arginine, threonine, valine, and tryptophan; the eighth amino acid residue is optionally substituted with aspartic acid, glycine, tyrosine, phenylalanine, serine, histidine, glutamic acid, glutamine, alanine, leucine, or analogs thereof, or an asparagine analog; the ninth amino acid residue is optionally substituted with an amino acid other than glycine, proline, and tryptophan; the tenth amino acid residue is optionally substituted with a branched chain amino acid other than isoleucine; the eleventh amino acid residue is optionally substituted with an amino acid other than glycine, proline, and tryptophan; the twelfth amino acid residue is optionally substituted with a tyrosine analog or a phenylalanine analog; the thirteenth amino acid residue is optionally substituted with alanine or an analog thereof, or a glycine analog; the fourteenth amino acid residue is optionally substituted with histidine, leucine, tyrosine, tryptophan, or analogs thereof, or a phenylalanine analog; and the fifteenth amino acid residue is optionally substituted with an aromatic amino acid other than tyrosine and histidine.

The present invention provides a microorganism that has been modified to express a gene encoding a protein having arginine:glycine amidinotransferase (AGAT) activity and increase the production of glycine from L-serine by enhancing L-serine hydroxymethyltransferase activity, as well as a method for producing guanidinoacetic acid (GAA) by fermentation of such a microorganism, and a method for producing creatine.

The invention discloses a preparation method and application of a biocompatible nano-enzyme with multiple-effect catalytic activity. The preparation method comprises the following steps: S1, synthesizing ultra-small nano-gold by using human serum albumin as a template; s2, synthesizing manganese dioxide nanoparticles by using human serum albumin as a template; s3, carrying out crosslinking on the synthesized ultra-small nanogold and manganese dioxide through bis (N-hydroxysuccinimide), so as to form a hybrid cluster-shaped nano enzyme with a relatively large size; and S4, after the nano enzyme is assembled, introducing cycloarginine-glycine-aspartic acid containing N-hydroxysuccinimide, so as to obtain the target ligand RGD modified nano enzyme. The hybrid cluster-shaped nano enzyme prepared by the invention has multiple-effect catalytic activity, blood-brain barrier penetrating capacity and photo-thermal characteristics, shows an effective synergistic treatment effect of a photo-thermal therapy, a chemical kinetic therapy and a starvation therapy, inhibits the development of glioblastoma, and keeps good biological safety at the same time.

The invention discloses a cyclic nonapeptide with skin barrier repairing and anti-inflammatory effects. The amino acid sequence of the cyclic nonapeptide is as follows: cyclic (arginine-glycine-aspartic acid-serine-arginine-lysine-valine-lysine-tryptophan). The cyclic nonapeptide disclosed by the invention can be used for improving the relative expression level of genes of LOR, FLG and AQP3 and reducing the secretion amount of inflammatory factors IL-6 and IL-8, so that the cyclic nonapeptide has skin barrier repairing and anti-inflammatory effects.

The invention discloses a cyclic nonapeptide with the effects of resisting light aging and resisting oxidation. The amino acid sequence of the cyclic nonapeptide is as follows: cyclic (arginine-glycine-aspartic acid-serine-asparagine-lysine-valine-lysine-phenylalanine). The cyclic nonapeptide disclosed by the invention can be used for effectively relieving deep photoaging caused by UVA and surface oxidative damage induced by UVB, so that comprehensive protection on skin is realized.

The present invention provides microorganisms that have been modified to express a gene encoding a protein having arginine:glycine amidinotransferase (AGAT) activity and to increase the production of glycine from L-serine, as well as methods for producing guanidinoacetic acid (GAA) by fermentation of such microorganisms, and methods for producing creatine.